Cited by

• Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.

  Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Tardy M, et al. Cochrane Database Syst Rev. 2014 Jul 9;2014(7):CD009268. doi: 10.1002/14651858.CD009268.pub2. Cochrane Database Syst Rev. 2014. PMID: 25007358 Free PMC article.
• Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

  Miller R. Miller R. Curr Neuropharmacol. 2009 Dec;7(4):315-30. doi: 10.2174/157015909790031184. Curr Neuropharmacol. 2009. PMID: 20514211 Free PMC article.
• The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia.

  Ulrich S, Wurthmann C, Brosz M, Meyer FP. Ulrich S, et al. Clin Pharmacokinet. 1998 Mar;34(3):227-63. doi: 10.2165/00003088-199834030-00005. Clin Pharmacokinet. 1998. PMID: 9533984 Review.
• Haloperidol dose for the acute phase of schizophrenia.

  Donnelly L, Rathbone J, Adams CE. Donnelly L, et al. Cochrane Database Syst Rev. 2013 Aug 28;2013(8):CD001951. doi: 10.1002/14651858.CD001951.pub2. Cochrane Database Syst Rev. 2013. PMID: 23983042 Free PMC article.
• Pharmacokinetics of haloperidol.

  Froemming JS, Lam YW, Jann MW, Davis CM. Froemming JS, et al. Clin Pharmacokinet. 1989 Dec;17(6):396-423. doi: 10.2165/00003088-198917060-00004. Clin Pharmacokinet. 1989. PMID: 2689040 Review.